Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,500Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,000Price:--
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Newell William JOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:167,000Price:--
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:37,100Price:--
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Albini Edward COwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:69,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit (RSU)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-8,750Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,500Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:38,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,108Price:$4.54
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,750Price:--
Filings by filing date
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Newell William JOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:167,000Price:--
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:37,100Price:--
-
Mar 05, 2024 (filed on Mar 22, 2024)Insider Name:Albini Edward COwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:69,000Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:16,500Price:--
-
Mar 07, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit (RSU)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-8,750Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Restricted Stock Units (RSUs)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,500Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:38,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,108Price:$4.54
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Fitzpatrick Linda AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:8,750Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 111 Oyster Point Blvd. SOUTH SAN FRANCISCO CA 94080 |
Tel: | 1-650-8015728 |
Website: | https://www.sutrobio.com |
IR: | See website |
Key People | ||
Jane Chung President, Chief Operating Officer | William J. Newell Chief Executive Officer, Director | Edward Albini Chief Financial Officer |
Linda A. Fitzpatrick Chief People and Communications Officer | Hans-Peter Gerber Chief Scientific Officer | Shabbir T. Anik Chief Technical Operations Officer |
Anne Borgman Chief Medical Officer | Brunilda Shtylla Chief Business Officer | Nicki J. Vasquez Chief Portfolio Strategy and Alliance Officer |
Business Overview |
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company's advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors. |
Financial Overview |
For the fiscal year ended 31 December 2023, Sutro Biopharma Inc revenues increased from $67.8M to $153.7M. Net loss decreased 10% to $106.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income increase from $3.5M to $14.5M (income), Stock-based Compensation in SGA decrease of 19% to $13.1M (expense). |
Employees: | 302 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $153.73M as of Dec 31, 2023 |
EBITDA (TTM): | -$82.46M as of Dec 31, 2023 |
Net annual income (TTM): | -$106.79M as of Dec 31, 2023 |
Free cash flow (TTM): | -$115.93M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 62,441,963 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |